Following a year of close and fruitful collaboration, our CEO Hugo Chrost has met in Boston with Bryan Katz - Senior VP & Global Head of New Solutions Development at Syneos Health. Ongoing work with Bryan, who is a member of our Advisory Board, has advanced our biomarker development and commercialisation efforts. Watch this space: we will announce soon a collaboration with a world-leading player.

Everything we do at Solvemed is strongly embedded in science. This is why we work closely with world-leading clinicians and clinical researchers, whose decades of professional experience guide our decision-making so we can create biomarker solutions that have a lasting meaningful impact on patient care and drug development.

It is amazing to see Bill Gates' commitment to fighting neurodegenerative diseases. New funding from Alzheimer's Drug Discovery Foundation will help the Early Detection of Neurodegenerative diseases (EDoN) initiative accelerate data collection and sharing to enable early detection and treatment.

Grateful to The Startup Pill for recognising Solvemed Group as one of ''44 Best Cambridgeshire Medical Device Startups Revolutionising Healthcare''.

Digital biomarkers provide an answer to the vast and fast-growing medical and R&D challenges in neurology. This is because objective, high-frequency data can guide critical decision-making in therapeutic development and allow for a more efficient evaluation of therapies of increasingly common disorders.

We are thrilled to announce that Solvemed Group has been invited to join NVIDIA's AI & Deep Learning accelerator. NVIDIA Inception is an acceleration platform for AI, data science and high-performance computing startups, providing critical go-to-market support, expertise, and technology.

We are thrilled to announce that Innovate UK EDGE East of England will provide Solvemed Group with its tailored Innovation Growth Support services! We are proud of this recognition and excited about the opportunity to strategically support our continuing growth in the UK.

We are excited to announce that Solvemed Group, following a very successful participation in this year's edition of the BIA PULSE programme, will be joining the BioIndustry Association (BIA) as a member. With more than 430 members, BIA serves as the voice of the UK Bioscience industry connecting individuals and organisations, helping to shape the future of the sector.

Team Solvemed is excited to announce today's signing of a Letter of Intent with the Polish Hospital Federation (Polska Federacja Szpitali) - an umbrella organization hosting for more than 500 member hospitals. Today, together with the Federation, we express the intent to promote the use of Solvemed's technuology in their entire hospital network.

Very happy to share that Solvemed Group was shortlisted as one of 9 companies from a cohort of 48 to pitch to a panel of selected industry partners and VC/Angel investors as part of the prestigious P4 Precision Medicine Accelerator programme. We are excited about this opportunity!

Last Friday, our Co-CEO Dr Michal Wlodarski joined Laura Modiano (Amazon) and Dr Marcos Gallego Llorente (Vintura) in a discussion panel as part of the #HealthcareDay organised by IESE Business School.

Solvemed Group is excited to announce the today's signing of a Letter of Intent (LoI) with one of the biggest private ophthalmological clinical in the CEE, Klinika Okulistyczna OFTALMIKA, located in central Poland. The LoI expresses commitment of both parties in implementing Solvemed's digital ocular biomarkers technology in their clinic. Many thanks to Drs, Jakub Kałużny and Bartlomiej Kaluzny for your confidence in our technology and in our collaboration.